SecBot SecBot
SECBOTREPLAY Home › Report › CRMD

CRMD · Heron asset buy + $50M loan

CorMedix Inc. · DEFA14A filed Nov 9, 2026 at 07:53 ET

At the news

NEUTRALIMPACT 6/10

DEFA14A filed Nov 9, 2026 at 07:53 ET

CorMedix entered into a loan agreement with BioPharma Credit for up to $50M in Tranche B term loans, and simultaneously signed an asset purchase agreement with Heron Therapeutics to acquire multiple commercial-stage products (Cinvanti, Zynrelef, Aponvie, Sustol) for $145M in cash plus 14,583,333 shares of CorMedix common stock. The loan proceeds are designated to fund the Heron acquisition and potential other acquisitions.

  • CorMedix entered a loan agreement with BioPharma Credit for up to $50M in Tranche B term loans dated November 8, 2026.
  • CorMedix signed an asset purchase agreement with Heron Therapeutics to acquire Cinvanti, Zynrelef, Aponvie, and Sustol.
  • Total cash consideration for the Heron acquisition is $145M plus 14,583,333 shares of CorMedix common stock.
  • The loan proceeds are to fund the Heron Acquisition Transaction and potential other acquisitions.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access